The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
South East (England); Surrey, East and West Sussex;
Location of affected unit(s)
Worthing, Crawley
Sector
(10 - 33) Manufacturing (20 - 21) Manufacture of chemicals and pharmaceuticals 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
300 jobs Number of planned job losses
Announcement Date
25 October 2007
Employment effect (start)
Foreseen end date
31 December 2009
Description
GlaxoSmithKline, the multi-national producer of pharmaceuticals, has announced that it is to cut 310 jobs at its sites in Worthing and Crawley. The firm has stated that the job losses are a result of the firm’s need to save 700 million GBP annually until 2010 in order to offset falling sales of its diabetes treatment Avandia. 180 job losses will be implemented at the Worthing site, whilst 130 job losses will be implemented at the Crawley site. The firm has stated that all of areas of the sites will be affected by the job losses, and has also stated that the job cuts will affect permanent positions as well as contracted positions. The job losses are due to be implemented by the end of 2009. Ian Holdstock, Director of the Crawley site stated, 'We regret the impact of this proposal, but would like to emphasise that [the] announcement is based on a review of the forecast volumes and the need to improve the efficiency of our operations… This is not a reflection of the performance of our employees. The site has a good customer service record and has contributed to a number of successful product launches this year. This is disappointing news but we are committed to supporting our staff though these difficult times.' GlaxoSmithKline employs 100,000 globally.
Sources
25 October 2007: BBC Website
Citation
Eurofound (2007), Glaxo Smith Kline, Internal restructuring in United Kingdom, factsheet number 65975, European Restructuring Monitor. Dublin, https://dev.eurofound.europa.eu/restructuring-events/detail/65975.
This working paper offers a comprehensive methodological overview of the European Restructuring Monitor (ERM) databases. Even though the methodology has not changed over time, new categories have been added, and the way it has been used by researchers and policymakers...
This Eurofound research paper explores key trends in restructuring in recent years, highlighting the companies that announced the largest job losses and job gains in the EU. It builds on an analysis of company announcements recorded in Eurofound’s European Restructuring...
In 2023, thousands of workers in big tech lost their jobs. Meta, Amazon, Google, Apple, Microsoft and Salesforce had been considered to offer good and secure jobs up to this point. Giants of the information and communication technology (ICT) sector,...
In 2024, the automotive sector in the EU came to the fore in public and policy discussions. The focus was on the slowdown in electric vehicle (EV) sales, rising global competition, belated investments in new technologies, and the potential closure...
The more employee monitoring resembles surveillance – with its systematic, continuous and detailed tracking of employees' activities, behaviours or communications – the greater the potential for infringement of both privacy and data protection rights. Although the EU General Data Protection...
Since 2013, Eurofound's ERM database on restructuring-related legislation has been documenting regulatory developments in the Member States of the European Union and Norway which are explicitly or implicitly linked to anticipating and managing change. The most recent update to the...